2022-07-28
Transcenta to Present Interim Safety and Efficacy Data of the TST001 and Chemotherapy Combination Expansion Cohort for Claudin18.2 Positive First Line Gastric Cancer at ESMO Congress 2022
SUZHOU, China, July 28, 2022 -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that the interim safety and efficacy data of dose expansion cohort from the phase I study of TST001, a humanized anti-Claudin18.2 monoclonal antibody, in combination with Capecitabine and Oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer will be presented at the European Society for Medical Oncology (ESMO) Congress 2022, which will be held on September 9-13, 2022. Details will be provided upon Embargo release later.